My bookmarksSign up free
Source

Commission Regulation (EU) 2016/863 of 31 May 2016 amending Annexes VII and VIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards skin corrosion/irritation, serious eye damage/eye irritation and acute toxicity (Text with EEA relevance)

Commission Regulation (EU) 2016/863 of 31 May 2016 amending Annexes VII and VIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards skin corrosion/irritation, serious eye damage/eye irritation and acute toxicity (Text with EEA relevance)

Regulation (EU) 2016/863 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annexes VII and VIII to Regulation (EC) No 1907/2006 are amended in accordance with the Annex to this Regulation.

Article 2

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Annexes VII and VIII to Regulation (EC) No 1907/2006 are amended as follows: (1) points 8.1 and 8.2 of Annex VII shall be replaced by the following: ‘8.1. Skin corrosion/irritation 8.1. The study/ies do(es) not need to be conducted if: — the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5) and the available information indicates that it should be classified as skin corrosion (Category 1), or — the substance is spontaneously flammable in air or in contact with water or moisture at room temperature, or — the substance is classified as acute toxicity by the dermal route (Category 1), or — an acute toxicity study by the dermal route does not indicate skin irritation up to the limit dose level (2 000 mg/kg body weight). If results from one of the two studies under point 8.1.1 or 8.1.2 already allow a conclusive decision on the classification of a substance or on the absence of skin irritation potential, the second study need not be conducted. 8.1.1. Skin corrosion, in vitro   8.1.2. Skin irritation, in vitro   8.2. Serious eye damage/eye irritation 8.2. The study/ies do(es) not need to be conducted if: — the substance is classified as skin corrosion, leading to classification as serious eye damage (Category 1), or — the substance is classified as skin irritation and the available information indicates that it should be classified as eye irritation (Category 2), or — the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5) and the available information indicates that it should be classified as serious eye damage (Category 1), or — the substance is spontaneously flammable in air or in contact with water or moisture at room temperature. 8.2.1. Serious eye damage/eye irritation, in vitro 8.2.1. If results from a first in vitro study do not allow a conclusive decision on the classification of a substance or on the absence of eye irritation potential, (an)other in vitro study/ies) for this endpoint shall be considered.’ (2) points 8.1 and 8.2 of Annex VIII shall be replaced by the following: ‘8.1. Skin corrosion/irritation 8.1. An in vivo study for skin corrosion/irritation shall be considered only if the in vitro studies under points 8.1.1 and 8.1.2 in Annex VII are not applicable, or the results of these studies are not adequate for classification and risk assessment. The study does not need to be conducted if: — the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5), or — the substance is spontaneously flammable in air or in contact with water or moisture at room temperature, or — the substance is classified as acute toxicity by the dermal route (Category 1), or — an acute toxicity study by the dermal route does not indicate skin irritation up to the limit dose level (2 000 mg/kg body weight). 8.2. Serious eye damage/eye irritation 8.2. An in vivo study for eye corrosion/irritation shall be considered only if the in vitro study(ies) under point 8.2.1 in Annex VII are not applicable, or the results obtained from these study(ies) are not adequate for classification and risk assessment. The study does not need to be conducted if: — the substance is classified as skin corrosion, or — the substance is a strong acid (pH ≤ 2,0) or base (pH ≥ 11,5), or — the substance is spontaneously flammable in air or in contact with water or moisture at room temperature.’ (3) point 8.5 of Annex VIII shall be replaced by the following: ‘8.5. Acute toxicity 8.5. The study/ies do(es) not generally need to be conducted if: — the substance is classified as skin corrosion. In addition to the oral route (Annex VII, 8.5.1.), for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route. The choice for the second route will depend on the nature of the substance and the likely route of human exposure. If there is only one route of exposure, information for only that route needs to be provided. 8.5.2. By inhalation 8.5.2. Testing by the inhalation route is appropriate if exposure of humans via inhalation is likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size. 8.5.3. By dermal route 8.5.3. Testing by the dermal route is appropriate if: (1) inhalation of the substance is unlikely; and (2) skin contact in production and/or use is likely; and (3) the physicochemical and toxicological properties suggest potential for a significant rate of absorption through the skin. Testing by the dermal route does not need to be conducted if: — the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and — no systemic effects have been observed in in vivo studies with dermal exposure (e.g. skin irritation, skin sensitisation) or, in the absence of an in vivo study by the oral route, no systemic effects after dermal exposure are predicted on the basis of non-testing approaches (e.g. read across, QSAR studies).’

Other acts of the same type
Commission Implementing Regulation (EU) 2022/685 of 28 April 2022 amending Regulation (EC) No 333/2007 as regards the sampling requirements for fish and terrestrial animals (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/686 of 28 April 2022 amending Implementing Regulations (EU) 2015/1295 and (EU) No 540/2011 as regards the conditions of approval of the active substance sulfoxaflor (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/680 of 27 April 2022 amending the information in the Annex to Implementing Regulation (EU) 2020/178 by including United Kingdom (Northern Ireland) as an origin for which a phytosanitary certificate is not required for the introduction into the Union of plants, fruits, vegetables, flowers or seedsCommission Implementing Regulation (EU) 2022/683 of 27 April 2022 amending Regulation (EC) No 1484/95 as regards fixing representative prices in the poultrymeat and egg sectors and for egg albuminCommission Implementing Regulation (EU) 2022/678 of 26 April 2022 amending Annexes V and XIV to Implementing Regulation (EU) 2021/404 as regards the entries for Canada, the United Kingdom and the United States in the lists of third countries authorised for the entry into the Union of consignments of poultry, germinal products of poultry and fresh meat of poultry and game birds (Text with EEA relevance)Commission Delegated Regulation (EU) 2022/1303 of 25 April 2022 amending Regulation (EU) 2019/787 of the European Parliament and of the Council as regards the definition of and requirements for ethyl alcohol of agricultural originCommission Implementing Regulation (EU) 2022/672 of 22 April 2022 amending Implementing Regulation (EU) 2017/2470 as regards the specifications of the novel food trans-resveratrol (from microbial source) (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/673 of 22 April 2022 authorising the placing on the market of mung bean (Vigna radiata) protein as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/674 of 22 April 2022 correcting Implementing Regulation (EU) 2022/95 imposing a definitive anti-dumping duty on imports of certain tube and pipe fittings, of iron or steel, originating in the People’s Republic of China, as extended to imports of certain tube and pipe fittings, of iron or steel consigned from Taiwan, Indonesia, Sri Lanka and the Philippines, whether declared as originating in these countries or not following an expiry review pursuant to Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the CouncilCommission Delegated Regulation (EU) 2022/1615 of 22 April 2022 correcting the Swedish language version of Delegated Regulation (EU) 2021/630 supplementing Regulation (EU) 2017/625 of the European Parliament and of the Council as regards certain categories of goods exempted from official controls at border control posts (Text with EEA relevance)Council Implementing Regulation (EU) 2022/658 of 21 April 2022 implementing Regulation (EU) No 269/2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of UkraineCouncil Implementing Regulation (EU) 2022/659 of 21 April 2022 implementing Regulation (EU) 2017/1509 concerning restrictive measures against the Democratic People’s Republic of Korea

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next